Inhibitor Development against p7 Channel in Hepatitis C Virus

Area of Science:

• Virology
• Medicinal Chemistry
• Drug Discovery

Background:

• Hepatitis C Virus (HCV) causes chronic liver disease, necessitating new drug development due to viral mutations.
• The HCV p7 viroporin protein is a potential target for antiviral therapies.
• Existing p7 inhibitors like amantadine have limited efficacy.

Purpose of the Study:

• To screen novel p7 inhibitors based on the amantadine scaffold.
• To identify potent inhibitors of HCV p7 for potential anti-HCV drug development.

Main Methods:

• Screening of novel ARD-series compounds targeting HCV p7.
• Determination of dissociation constants (Kd) using nuclear magnetic resonance (NMR) titrations.
• Viral production assays, molecular dynamics (MD) simulations, and molecular docking analyses.

Main Results:

• 42 ARD-series compounds were evaluated for p7 inhibition.
• ARD87 and ARD112 demonstrated significant efficacy in viral production assays.
• Molecular simulations revealed hydrophobic interactions as key to inhibition potency.

Conclusions:

• Novel p7 inhibitors with improved affinity were identified.
• Functional groups and hydrophobic interactions are critical for HCV p7 inhibition.
• Findings provide a basis for designing next-generation anti-HCV drug candidates.